Neumora Therapeutics, Inc. Share Price: NMRA (Neumora Therapeutics, Inc.) Stock Price Today & Updates | INDmoney

Question 1

What is Neumora Therapeutics, Inc. share price today?

Accepted Answer

Neumora Therapeutics, Inc. (NMRA) share price today is {{live_price}}.

Question 2

Can Indians buy Neumora Therapeutics, Inc. shares?

Accepted Answer

Yes, Indians can invest in the Neumora Therapeutics, Inc. (NMRA) from India.

With INDmoney, you can buy Neumora Therapeutics, Inc. at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Neumora Therapeutics, Inc. at zero transaction cost.

Question 3

How can I buy Neumora Therapeutics, Inc. shares from India?

Accepted Answer

It is very easy to buy Neumora Therapeutics, Inc. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Question 4

Can Fractional shares of Neumora Therapeutics, Inc. be purchased?

Accepted Answer

Yes, you can buy fractional shares of Neumora Therapeutics, Inc. with INDmoney app.

Question 5

What are the documents required to start investing in Neumora Therapeutics, Inc. stocks?

Accepted Answer

To start investing in Neumora Therapeutics, Inc., You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

Question 6

What are today’s High and Low prices of Neumora Therapeutics, Inc.

Accepted Answer

Today’s highest price of Neumora Therapeutics, Inc. (NMRA) is {{1_rba_end}}.

Today’s lowest price of Neumora Therapeutics, Inc. (NMRA) is {{1_rba_st}}.

Question 7

What is today's market capitalisation of Neumora Therapeutics, Inc.

Accepted Answer

Today's market capitalisation of Neumora Therapeutics, Inc. NMRA is 2.4B

Question 8

What is the 52 Week High and Low Range of Neumora Therapeutics, Inc.

Accepted Answer

52 Week High
{{rba_end}}
52 Week Low
{{rba_st}}

Question 9

How much percentage Neumora Therapeutics, Inc. is down from its 52 Week High?

Accepted Answer

Neumora Therapeutics, Inc. (NMRA) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

Question 10

How much percentage Neumora Therapeutics, Inc. is up from its 52 Week low?

Accepted Answer

Neumora Therapeutics, Inc. (NMRA) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

Question 11

What are the historical returns of Neumora Therapeutics, Inc.?

Accepted Answer

1 Month Returns
{{1mr}}%
3 Months Returns
{{3mr}}%
1 Year Returns
{{1yr}}%
5 Years Returns
{{5yr}}%

Question 12

Who is the Chief Executive Officer (CEO) of Neumora Therapeutics, Inc.

Accepted Answer

Mr. Paul L. Berns is the current Chief Executive Officer (CEO) of Neumora Therapeutics, Inc..

Period	Neumora Therapeutics, Inc.
3 Months	41.22%
6 Months	0.14%
1 Year	21.94%
3 Years	-10.4%

Market Capitalization	2.4B
Book Value	$2.38
Earnings Per Share (EPS)	-1.72
Wall Street Target Price	24.86

Profit Margin	0.0%
Operating Margin TTM	0.0%

Return On Assets TTM	-37.75%
Return On Equity TTM	-77.08%

Revenue TTM	0.0
Revenue Per Share TTM	0.0
Quarterly Revenue Growth YOY	0.0%
Gross Profit TTM	0.0
EBITDA	-230.2M
Diluted Eps TTM	-1.72
Quarterly Earnings Growth YOY	0.0

Neumora Therapeutics, Inc. (NMRA)

Performance

Returns

Highlights

Analyst Recommendation

Analyst Forecast

Technicals Summary

Peers

Company Information

Discover More

FAQs

EPS Estimate Current Year	-1.48
EPS Estimate Next Year	-1.55
EPS Estimate Current Quarter	-0.37
EPS Estimate Next Quarter	-0.4

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Neumora Therapeutics, Inc.	27.61%	0.14%	21.94%	-10.4%	-10.4%
Regeneron Pharmaceuticals, Inc.	-12.19%	6.5%	20.85%	84.03%	245.65%
Novo Nordisk A/s	-11.15%	-6.13%	27.31%	138.21%	354.53%
Alnylam Pharmaceuticals, Inc.	5.38%	73.95%	61.12%	32.59%	252.19%
Vertex Pharmaceuticals Incorporated	-2.58%	13.46%	29.21%	155.56%	172.0%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Neumora Therapeutics, Inc.	NA	NA	NA	-1.48	-0.77	-0.38	NA	2.38
Regeneron Pharmaceuticals, Inc.	26.37	26.37	1.36	45.03	0.17	0.08	NA	261.41
Novo Nordisk A/s	38.76	38.76	1.75	3.39	0.89	0.23	0.01	25.24
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-2.49	-15.01	0.02	NA	-0.02
Vertex Pharmaceuticals Incorporated	32.84	NA	0.54	0.32	-0.03	0.13	NA	57.26

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Neumora Therapeutics, Inc.	Buy	$2.4B	-10.4%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$109.8B	245.65%	26.37	32.04%
Novo Nordisk A/s	Buy	$512.4B	354.53%	38.76	34.84%
Alnylam Pharmaceuticals, Inc.	Buy	$34.2B	252.19%	NA	-3.11%
Vertex Pharmaceuticals Incorporated	Buy	$115.8B	172.0%	32.84	-4.74%

Organization	Neumora Therapeutics, Inc.
Employees	108
CEO	Mr. Paul L. Berns
Industry	Miscellaneous